Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD10 | O75832 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15543885 | 0.90 | PSMD10 (0.37) | PSMD10POLBL3MBTL1MMP2MMP9 | |
| SCHEMBL16343251 | 0.89 | CYP19A1 (0.30) | — | |
| SCHEMBL15544213 | 0.88 | PSMD10 (0.37) | PSMD10MMP2MMP9MMP8MMP13 | |
| SCHEMBL15545174 | 0.88 | THRB (0.32) | — | |
| SCHEMBL15544080 | 0.86 | EGFR (0.44) | EGFRERBB2 | |
| SCHEMBL15608185 | 0.84 | CYP19A1 (0.32) | — | |
| SCHEMBL16367366 | 0.84 | CYP19A1 (0.32) | — | |
| SCHEMBL15544602 | 0.83 | PKM (0.35) | PSMD10POLBL3MBTL1MMP2MMP9 | |
| SCHEMBL15545349 | 0.81 | BCHE (0.36) | PSMD10POLB | |
| SCHEMBL15607852 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| EP-2793871-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | Auckland Uniservices Limited (NZ) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014007650-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | PSMD10 4424/4885POLB 1684/4885L3MBTL1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.